Opportunity Information: Apply for W81XWH 20 GWIRP CEA
The Department of Defense Gulf War Illness Research Program (GWIRP) Clinical Evaluation Award (FY20) is designed to move the most solid Gulf War Illness (GWI) research closer to real-world use by testing it directly in Gulf War Veteran populations. The opportunity sits in the "Verification" stage of the GWIRP research pipeline, meaning it is not aimed at early discovery work but at evaluating and confirming findings that already have meaningful supporting evidence. In practice, this includes translating validated GWI research and qualified, replicated preclinical results into clinical evaluation studies that can show whether proposed biomarkers or interventions hold up when tested with Veterans who have GWI.
A major priority for this award is clinical biomarker work that is statistically powered and capable of validating biomarkers as clinical endpoints. This includes large-scale clinical biomarker studies and biomarker trials that can help determine whether measurable biological indicators can reliably track disease status, subgroup patients, or reflect response to treatment. The award also encourages proof-of-concept intervention trials, such as pilot studies, first-in-human efforts, or Phase I to early Phase IIa trials. Treatments repurposed from other disorders with overlapping symptoms may be considered, but the program preference is clearly toward projects that build on results generated within the GWI research community and that translate already qualified findings rather than starting from scratch.
A non-negotiable requirement is that award funds must support research conducted in a Gulf War Veteran population. Applicants also have to provide evidence that they can actually access the needed Veteran cohort(s) and any critical reagents or resources required to complete the study, which is essentially meant to prevent proposals that look good on paper but cannot recruit or execute. The program also points applicants to DoD-provided outreach and recruitment best practices for engaging Gulf War Veterans, signaling that recruitment feasibility and Veteran-centered practices are taken seriously in review.
The Areas of Emphasis reflect the program's strong interest in clinically translating both treatments and biological indicators/targets tied to dysregulated system function. The opportunity highlights a wide range of symptom domains commonly seen in GWI, including cognitive problems (memory deficits, mood and behavioral disturbances), non-restorative sleep and sleep disruption, chronic widespread pain, severe fatigue, gastrointestinal problems (including dietary intolerances, GERD, and functional GI disorders), sinus and respiratory issues, headaches, dermatological conditions, and neurological dysfunction spanning central, peripheral, autonomic, and neuromuscular systems. It also calls out immune dysfunction, endocrine/exocrine/excretory dysfunction with particular attention to kidney and liver issues (including Cytochrome P450 abnormalities), microbiome variants, and the way stressors like exertion or immune challenge can worsen symptoms. Another emphasized concept is "disordered system crosstalk," such as immune disruption affecting the nervous system or autonomic dysfunction altering GI function, with the larger goal of understanding why multiple physiological systems may be affected at once. Beyond symptom-focused research, the announcement highlights interest in validating molecular signatures (genomic, proteomic, metabolic, epigenetic) that may underlie symptoms and could help define biologically meaningful subgroups, as well as investigating comorbidities, mortality, and differences by sex or ethnicity. While the announcement lists these priorities, it also makes clear applicants can propose other GWI-relevant clinical evaluation studies aligned with the GWIRP mission and overarching challenges.
Two collaboration-oriented options can increase the allowable budget if the project meets additional requirements. The Biorepository Contribution Option encourages applicants to contribute Gulf War Veteran biospecimens and associated data to the established Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI, which is intended to support long-term sharing and reuse of specimens and data across the field. Separately, the Clinical Consortium Collaboration Option encourages investigators to use the infrastructure of the Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC), such as recruitment networks, established protocols, Common Data Elements, and data management procedures. This consortium option requires a letter of collaboration from GWICTIC describing what resources or services will be shared and how that adds value. Importantly, if an applicant uses the consortium collaboration option, they cannot also apply under the biorepository contribution option, because consortium projects must follow GWICTIC policies on biospecimens and data.
The announcement also spells out what it will not fund. It does not support studies that treat psychiatric disease or psychological stress as the primary cause of GWI, nor does it support implementing care guidelines that heavily emphasize psychiatric pathologies or psychiatric remedies. It also does not support applications focused on amyotrophic lateral sclerosis (ALS) as a main topic, although Veterans with ALS can be included if ALS is part of the study's GWI case definition and the research remains focused on GWI symptomatology. Applicants who want to do ALS-focused work are directed to the separate ALS Research Program.
From a funding and administrative standpoint, awards are made as assistance agreements, meaning either grants or cooperative agreements depending on how much involvement the DoD anticipates having during the project. If there is no substantial agency involvement, the mechanism is a grant; if substantial involvement is expected (for example, collaboration or participation in aspects of the research), it becomes a cooperative agreement. For budgeting, anticipated direct costs for the entire performance period are capped at $1.5 million for the standard award, up to $1.52 million with the Biorepository Contribution Option, and up to $1.7 million with the Clinical Consortium Collaboration Option. The Department of Defense indicated it expected to allocate about $4.8 million total to support roughly two awards, with final funding dependent on federal appropriations, application volume, and scientific and programmatic review outcomes.
Key dates and logistics are also clearly stated in the source information. The opportunity (W81XWH-20-GWIRP-CEA) was posted March 24, 2020 and had an original closing date of September 10, 2020. Awards were expected to be made no later than September 30, 2021. The funding was expected to be drawn from FY20 funds, which were anticipated to remain available for use until September 30, 2026, shaping the practical window for spending and project execution planning. Eligible applicants were described as unrestricted (open to any entity type, subject to any additional eligibility clarifications in the full announcement), and the administering agency was the Department of Defense, Department of the Army, USAMRAA, under CFDA 12.420.Apply for W81XWH 20 GWIRP CEA
- The Department of Defense, Dept. of the Army -- USAMRAA in the science and technology and other research and development sector is offering a public funding opportunity titled "DoD Gulf War Illness, Clinical Evaluation Award" and is now available to receive applicants.
- Interested and eligible applicants and submit their applications by referencing the CFDA number(s): 12.420.
- This funding opportunity was created on Mar 24, 2020.
- Applicants must submit their applications by Sep 10, 2020. (Agency may still review applications by suitable applicants for the remaining/unused allocated funding in 2026.)
- The number of recipients for this funding is limited to 2 candidate(s).
- Eligible applicants include: Unrestricted (i.e., open to any type of entity above), subject to any clarification in text field entitled Additional Information on Eligibility.
[Watch] Creating a grant proposal using the step-by-step wizard inside the applicant portal:
FAQs: DoD Gulf War Illness Research Program (GWIRP) Clinical Evaluation Award (FY20)
What is the GWIRP Clinical Evaluation Award (FY20) meant to do?
The GWIRP Clinical Evaluation Award (FY20) is intended to move the strongest Gulf War Illness (GWI) research closer to real-world use by testing it directly in Gulf War Veteran populations. It supports clinical evaluation studies that verify and confirm findings that already have meaningful supporting evidence, rather than early-stage discovery work.
What stage of research does this opportunity support?
This award sits in the "Verification" stage of the GWIRP research pipeline. That means it is focused on evaluating and confirming previously supported or validated findings, including translating replicated and qualified preclinical results into clinical evaluation studies in Veterans with GWI.
Does the research have to be conducted in Gulf War Veterans?
Yes. A non-negotiable requirement is that award funds must support research conducted in a Gulf War Veteran population.
Do applicants need to show they can recruit Gulf War Veterans?
Yes. Applicants must provide evidence that they can access the needed Veteran cohort(s). The opportunity also emphasizes the importance of recruitment feasibility and points applicants toward DoD-provided outreach and recruitment best practices for engaging Gulf War Veterans.
What kinds of studies are prioritized under this award?
The program highlights two major priorities: (1) statistically powered clinical biomarker work capable of validating biomarkers as clinical endpoints, and (2) proof-of-concept intervention trials (such as pilot studies, first-in-human efforts, or Phase I to early Phase IIa trials).
What does "clinical biomarker work" mean in the context of this opportunity?
It refers to large-scale clinical biomarker studies and biomarker trials designed to determine whether measurable biological indicators can reliably track disease status, identify biologically meaningful subgroups, or reflect response to treatment. A specific emphasis is placed on studies that are statistically powered and can validate biomarkers as clinical endpoints.
Are intervention trials allowed, and what types are encouraged?
Yes. The award encourages proof-of-concept intervention trials, including pilot studies, first-in-human efforts, and Phase I to early Phase IIa trials.
Can a project propose a treatment repurposed from another disorder?
Treatments repurposed from other disorders with overlapping symptoms may be considered. However, the program preference is for projects that build on results generated within the GWI research community and translate already qualified findings rather than starting from scratch.
What symptom areas and biological systems are included in the Areas of Emphasis?
The announcement highlights a wide range of GWI-relevant domains, including cognitive problems (memory deficits, mood and behavioral disturbances), non-restorative sleep and sleep disruption, chronic widespread pain, severe fatigue, gastrointestinal problems (dietary intolerances, GERD, functional GI disorders), sinus and respiratory issues, headaches, dermatological conditions, and neurological dysfunction across central, peripheral, autonomic, and neuromuscular systems.
Does the opportunity emphasize immune, endocrine, or other system dysfunction?
Yes. It calls out immune dysfunction and endocrine/exocrine/excretory dysfunction, with particular attention to kidney and liver issues, including Cytochrome P450 abnormalities. It also highlights microbiome variants and the way stressors (such as exertion or immune challenge) can worsen symptoms.
What is meant by "disordered system crosstalk"?
The opportunity emphasizes the idea that dysfunction in one system may influence another, such as immune disruption affecting the nervous system or autonomic dysfunction altering gastrointestinal function. The broader goal is to help explain why multiple physiological systems may be affected at once in GWI.
Are molecular signatures and subgrouping part of the program interests?
Yes. The announcement highlights interest in validating molecular signatures (genomic, proteomic, metabolic, epigenetic) that may underlie symptoms and help define biologically meaningful subgroups.
Does the opportunity mention comorbidities or population differences?
Yes. It notes interest in investigating comorbidities, mortality, and differences by sex or ethnicity.
Are applicants limited only to the listed Areas of Emphasis?
No. While the announcement lists priorities, it also states that applicants can propose other GWI-relevant clinical evaluation studies aligned with the GWIRP mission and overarching challenges.
What kinds of studies are explicitly not supported?
The opportunity does not support studies that treat psychiatric disease or psychological stress as the primary cause of GWI. It also does not support implementing care guidelines that heavily emphasize psychiatric pathologies or psychiatric remedies.
Is amyotrophic lateral sclerosis (ALS) research allowed under this opportunity?
Applications focused on ALS as a main topic are not supported under this award. Veterans with ALS can be included only if ALS is part of the study's GWI case definition and the research remains focused on GWI symptomatology. ALS-focused work is directed to the separate ALS Research Program.
What collaboration options are available to increase the allowable budget?
Two options are described: the Biorepository Contribution Option (contributing Gulf War Veteran biospecimens and associated data to BBRAIN) and the Clinical Consortium Collaboration Option (using infrastructure from the Gulf War Illness Clinical Trials and Interventions Consortium, or GWICTIC).
What is the Biorepository Contribution Option and what is BBRAIN?
The Biorepository Contribution Option encourages applicants to contribute Gulf War Veteran biospecimens and associated data to the established Boston Biorepository, Recruitment, and Integrative Network (BBRAIN) for GWI. The goal is to support long-term sharing and reuse of specimens and data across the field.
What is the Clinical Consortium Collaboration Option (GWICTIC) and what does it provide?
This option encourages investigators to use the infrastructure of the Gulf War Illness Clinical Trials and Interventions Consortium (GWICTIC), such as recruitment networks, established protocols, Common Data Elements, and data management procedures.
Is documentation required to use the Clinical Consortium Collaboration Option?
Yes. The consortium option requires a letter of collaboration from GWICTIC describing what resources or services will be shared and how that adds value.
Can an applicant use both the Biorepository Contribution Option and the Clinical Consortium Collaboration Option?
No. If an applicant uses the consortium collaboration option, they cannot also apply under the biorepository contribution option because consortium projects must follow GWICTIC policies on biospecimens and data.
What are the direct cost caps for this award?
Anticipated direct costs for the entire performance period are capped at $1.5 million for the standard award, up to $1.52 million with the Biorepository Contribution Option, and up to $1.7 million with the Clinical Consortium Collaboration Option.
How much total funding did DoD expect to allocate, and how many awards were anticipated?
The Department of Defense indicated it expected to allocate about $4.8 million total to support roughly two awards, with final funding dependent on federal appropriations, application volume, and scientific and programmatic review outcomes.
What funding mechanism is used (grant vs cooperative agreement)?
Awards are made as assistance agreements, meaning either grants or cooperative agreements depending on anticipated DoD involvement. If no substantial agency involvement is expected, the mechanism is a grant. If substantial involvement is expected, the mechanism is a cooperative agreement.
What is the opportunity number and who administers it?
The opportunity is W81XWH-20-GWIRP-CEA. The administering agency is the Department of Defense, Department of the Army, USAMRAA, under CFDA 12.420.
When was this opportunity posted and when did it close?
It was posted March 24, 2020, with an original closing date of September 10, 2020.
When were awards expected to be made?
Awards were expected to be made no later than September 30, 2021.
How long were FY20 funds expected to remain available?
Funding was expected to be drawn from FY20 funds anticipated to remain available for use until September 30, 2026, which shapes the practical window for spending and project execution planning.
Who is eligible to apply based on the provided information?
Eligible applicants were described as unrestricted (open to any entity type), subject to any additional eligibility clarifications in the full announcement.
What kinds of resources must applicants show they have access to?
Applicants must provide evidence of access to the required Gulf War Veteran cohort(s) and any critical reagents or resources needed to complete the study, to demonstrate the project can realistically recruit and execute.
Browse more opportunities from the same category: Science and Technology and other Research and Development
Next opportunity: Nevada Wildlife Resource Management
Previous opportunity: DoD Autism, Clinical Translational Research Award
Applicant Portal:
Are you interested in learning about about how to apply for this government funding opportunity? You can create a free applicant account and receive instant access to our applicant portal that many business owners like you have benefited from.
Apply for W81XWH 20 GWIRP CEA
Applicants also applied for:
Applicants who have applied for this opportunity (W81XWH 20 GWIRP CEA) also looked into and applied for these:
| Funding Opportunity |
|---|
| DoD Gulf War Illness, Patient-Provider and Health Communications Award Apply for W81XWH 20 GWIRP PPHCA Funding Number: W81XWH 20 GWIRP PPHCA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Gulf War Illness, Idea Award Apply for W81XWH 20 GWIRP IA Funding Number: W81XWH 20 GWIRP IA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Gulf War Illness, Therapeutic/Biomarker Trial Award Apply for W81XWH 20 GWIRP TBTA Funding Number: W81XWH 20 GWIRP TBTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Science and Technology Projects Related to Coal Mining and Reclamation Apply for S20AS00005 Funding Number: S20AS00005 Agency: Department of the Interior, Office of Surface Mining Category: Science and Technology and other Research and Development Funding Amount: $200,000 |
| Disability and Rehabilitation Research Projects (DRRP) Program: Center on Knowledge Translation for Employment Research Apply for HHS 2020 ACL NIDILRR DPEM 0395 Funding Number: HHS 2020 ACL NIDILRR DPEM 0395 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $500,000 |
| Disability and Rehabilitation Research Projects (DRRP): Assistive Technology to Promote Independence and Community Living Apply for HHS 2020 ACL NIDILRR DPGE 0415 Funding Number: HHS 2020 ACL NIDILRR DPGE 0415 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $500,000 |
| Demographic, Movement, and Habitat Studies of the Endangered Snail Kite in Response to Operational Plans in WCA 3A Apply for W81EWF 20 SOI 0014 Funding Number: W81EWF 20 SOI 0014 Agency: Department of Defense, Engineer Research and Development Center Category: Science and Technology and other Research and Development Funding Amount: $435,000 |
| The Small Business Innovation Research (SBIR) Program Phase II Apply for 2020 NIST SBIR 02 Funding Number: 2020 NIST SBIR 02 Agency: Department of Commerce, National Institute of Standards and Technology Category: Science and Technology and other Research and Development Funding Amount: $400,000 |
| Small Business Innovation Research Program (SBIR) Phase II Apply for HHS 2020 ACL NIDILRR BISB 0400 Funding Number: HHS 2020 ACL NIDILRR BISB 0400 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $575,000 |
| Maintenance of a Centralized PIT tag Database for the San Juan and Upper Basin Recovery Programs Apply for BOR UC 20 N001 Funding Number: BOR UC 20 N001 Agency: Department of the Interior, Bureau of Reclamation Category: Science and Technology and other Research and Development Funding Amount: $183,397 |
| DoD Orthotics and Prosthetics Outcomes, Clinical Research Award Apply for W81XWH 20 OPORP CRA Funding Number: W81XWH 20 OPORP CRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Orthotics and Prosthetics Outcomes, Clinical Trial Award Apply for W81XWH 20 OPORP CTA Funding Number: W81XWH 20 OPORP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Neurofibromatosis, Exploration- Hypothesis Development Award Apply for W81XWH 20 NFRP EHDA Funding Number: W81XWH 20 NFRP EHDA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Neurofibromatosis, Early Investigator Research Award Apply for W81XWH 20 NFRP EIRA Funding Number: W81XWH 20 NFRP EIRA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Neurofibromatosis, New Investigator Award Apply for W81XWH 20 NFRP NIA Funding Number: W81XWH 20 NFRP NIA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| DoD Neurofibromatosis, Clinical Trial Award Apply for W81XWH 20 NFRP CTA Funding Number: W81XWH 20 NFRP CTA Agency: Department of Defense, Dept. of the Army -- USAMRAA Category: Science and Technology and other Research and Development Funding Amount: Case Dependent |
| Invasive Species Support at JBMDL Apply for W9126G 20 2 SOI 3061 Funding Number: W9126G 20 2 SOI 3061 Agency: Department of Defense, Fort Worth District Category: Science and Technology and other Research and Development Funding Amount: $903,084 |
| HERO Appendix E: Topics in Human Factors and Behavioral Performance Apply for 80JSC019N0001 HFBP Funding Number: 80JSC019N0001 HFBP Agency: National Aeronautics and Space Administration, NASA Johnson Space Center Category: Science and Technology and other Research and Development Funding Amount: $1,400,000 |
| HERO Appendix F: NASA Human Research Program Omnibus Opportunity Apply for 80JSC019N0001 OMNIBUS3 Funding Number: 80JSC019N0001 OMNIBUS3 Agency: National Aeronautics and Space Administration, NASA Johnson Space Center Category: Science and Technology and other Research and Development Funding Amount: $150,000 |
| Rehabilitation Research and Training Center (RRTC): Employment of People Who are Blind or Have Low Vision Apply for HHS 2020 ACL NIDILRR RTEM 0388 Funding Number: HHS 2020 ACL NIDILRR RTEM 0388 Agency: Department of Health and Human Services, Administration for Community Living Category: Science and Technology and other Research and Development Funding Amount: $875,000 |
Grant application guides and resources
It is always free to apply for government grants. However the process may be very complex depending on the funding opportunity you are applying for. Let us help you!
Apply for Grants
Inside Our Applicants Portal
Access Applicants Portal
- Grants Repository - Access current and historic funding opportunities with ease. Thousands of funding opportunities are published every week. We can help you sort through the database and find the eligible ones to apply for.
- Applicant Video Guides - The grant application process can be challenging to follow. We can help you with intuitive video guides to speed up the process and eliminate errors in submissions.
- Grant Proposal Wizard - We have developed a network of private funding organizations and investors across the United States. We can reach out and submit your proposal to these contacts to maximize your chances of getting the funding you need.
Premium leads for funding administrators, grant writers, and loan issuers
Thousands of people visit our website for their funding needs every day. When a user creates a grant proposal and files for submission, we pass the information on to funding administrators, grant writers, and government loan issuers.
If you manage government grant programs, provide grant writing services, or issue personal or government loans, we can help you reach your audience.
Learn More
Request more information:
Would you like to learn more about this funding opportunity, similar opportunities to "W81XWH 20 GWIRP CEA", eligibility, application service, and/or application tips? Submit an inquiry below:
Don't forget to subscribe to our grant alerts mailing list to receive weekly alerts on new and updated grant funding opportunities like this one in your email.